Celemics

Celemics Debt/EBITDA

The Total Debt to EBITDA Ratio of Celemics (331920.KQ) as of Nov 2, 2026 is -0.11. In the previous year, Total Debt to EBITDA Ratio was -0.10 — a change of 12.67% (lower).

Debt/EBITDA

-0.11

YoY

12.67%

Last updated:

Total Debt to EBITDA Ratio of Celemics is 2024 -0.11 . Total Debt to EBITDA Ratio of Celemics was 2023 -0.10 . It decreases by 12.67% lower compared to the previous year.

The Celemics Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
-2.54 KRW
Jan 1, 2018
-3.88 KRW
Jan 1, 2019
-0.20 KRW
Jan 1, 2020
-0.00 KRW
Jan 1, 2021
-0.22 KRW
Jan 1, 2022
-0.17 KRW
Jan 1, 2023
-0.10 KRW
Jan 1, 2024
-0.11 KRW
The Celemics Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.11+12.67%
-0.10-40.25%
-0.17-25.15%
-0.22+4,985.67%
-0.00-97.75%
-0.20-94.95%
-3.88+52.38%
-2.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

Total Debt to EBITDA Ratio of Celemics is -0.11 in 2024.

Total Debt to EBITDA Ratio of Celemics changed from -0.10 to -0.11, representing a 12.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Celemics since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Celemics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Celemics

All Key Metrics — Celemics